BioPharma Resources

Drug Trial Radar · NCT02333331

Dose Range Finding Study of Bimagrumab in Sarcopenia

A 28 Week, Randomized, Double-blind, Placebo-controlled, Two-part, Multi-center, Parallel Group Dose Range Finding Study to Assess the Effect of Monthly Doses of Bimagrumab 70, 210, and 700 mg on Skeletal Muscle Strength and Function in Older Adults With Sarcopenia (InvestiGAIT)

Last checked: Nov 19, 2026Latest source record: Jan 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 217 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

217

Actual

Start

Dec 9, 2014

Primary completion

Jun 26, 2018

Study completion Jun 28, 2018

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 7, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to determine the efficacy of repeat dosing with multiple dose levels of bimagrumab on patient physical function, skeletal muscle mass and strength in older adults with sarcopenia. In addition, this study generated data on the safety, tolerability, and pharmacokinetics of bimagrumab in older adults with sarcopenia.

Conditions

  • Sarcopenia

Interventions

  • bimagrumabDrug

    Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.

  • placeboOther

    Placebo will be administered as an intravenous infusion starting on Day 1 until week 21.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Total Short Physical Performance Battery (SPPB) Score to Week 25Time frame: Baseline, week 25

Locations

58 sites in 13 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Little Rock, Arkansas

  • Novartis Investigative Site

    Cypress, California

  • Novartis Investigative Site

    La Jolla, California

  • Novartis Investigative Site

    Farmington, Connecticut

  • Novartis Investigative Site

    Gainesville, Florida

  • Novartis Investigative Site

    Miami, Florida

  • Novartis Investigative Site

    Miami Lakes, Florida

  • Novartis Investigative Site

    Orlando, Florida

  • Novartis Investigative Site

    Gainesville, Georgia

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Rochester, Minnesota

  • Novartis Investigative Site

    High Point, North Carolina

  • Novartis Investigative Site

    Columbus, Ohio

  • Novartis Investigative Site

    Spartanburg, South Carolina

  • Novartis Investigative Site

    Mesquite, Texas

  • Novartis Investigative Site

    San Antonio, Texas

  • Novartis Investigative Site

    Madison, Wisconsin

  • Novartis Investigative Site

    Adelaide, South Australia, Australia

  • Novartis Investigative Site

    St Albans, Victoria, Australia

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Brno, Czechia

  • Novartis Investigative Site

    Opava, Czechia

  • Novartis Investigative Site

    Prague, Czechia

  • Novartis Investigative Site

    Copenhagen, Denmark

  • Novartis Investigative Site

    Copenhagen NV, Denmark

  • Novartis Investigative Site

    Montpellier, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Pessac, France

  • Novartis Investigative Site

    Toulouse, France

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Würzburg, Germany

  • Novartis Investigative Site

    Ōbu, Aichi-ken, Japan

  • Novartis Investigative Site

    Toyohashi, Aichi-ken, Japan

  • Novartis Investigative Site

    Mizunami, Gifu, Japan

  • Novartis Investigative Site

    Nara, Nara, Japan

  • Novartis Investigative Site

    Kawachi-Nagano, Osaka, Japan

  • Novartis Investigative Site

    Kitaadachigun Inamachi, Saitama, Japan

  • Novartis Investigative Site

    Kitamoto, Saitama, Japan

  • Novartis Investigative Site

    Yoshinogawa, Tokushima, Japan

Showing 40 of 58 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.